BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ONC upcoming catalysts
BeOne Medicines: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 1 FDA event(s). Subscribe to ONC (.ics).
Drugs: Zanubrutinib, Sonrotoclax, Tislelizumab, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide, Temozolomide, Fruquintinib, Zanidatamab, Lenvatinib, bendamustine, rituximab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-31 est. | P3 | BeOne Medicines ONC | NCT04170283 A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutini | B-cell Malignancies | active not recruiting | 955 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-05-13 | FDA approval | approved | BEONE MEDICINES USA ONC | BEQALZI | Approved 2026-05-13: BEQALZI (NDA220711 ORIG1) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | BeOne Medicines ONC | NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | active not recruiting | 94 |
| 2026-11 est. | P1/P2 | BeOne Medicines ONC | NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, an | Relapsed/Refractory Multiple Myeloma | recruiting | 246 |
| 2026-09-22 | P2 | BeOne Medicines ONC | NCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglo | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobuli | active not recruiting | 114 |
| 2026-05-23 | P3 | BeOne Medicines ONC | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | Advanced Malignancies | completed | 404 |
| 2026-04-27 | P3 | BeOne Medicines ONC | NCT04002297 A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lym | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | active not recruiting | 510 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.